Spondylitis, Ankylosing: A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.Spondylitis: Inflammation of the SPINE. This includes both arthritic and non-arthritic conditions.HLA-B27 Antigen: A specific HLA-B surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-B*27 allele family.Sacroiliac Joint: The immovable joint formed by the lateral surfaces of the SACRUM and ILIUM.Spine: The spinal or vertebral column.Spondylarthritis: Inflammation of the joints of the SPINE, the intervertebral articulations.Antirheumatic Agents: Drugs that are used to treat RHEUMATOID ARTHRITIS.Spondylarthropathies: Heterogeneous group of arthritic diseases sharing clinical and radiologic features. They are associated with the HLA-B27 ANTIGEN and some with a triggering infection. Most involve the axial joints in the SPINE, particularly the SACROILIAC JOINT, but can also involve asymmetric peripheral joints. Subsets include ANKYLOSING SPONDYLITIS; REACTIVE ARTHRITIS; PSORIATIC ARTHRITIS; and others.Blood Sedimentation: Measurement of rate of settling of erythrocytes in anticoagulated blood.ArthritisIritis: Inflammation of the iris characterized by circumcorneal injection, aqueous flare, keratotic precipitates, and constricted and sluggish pupil along with discoloration of the iris.Severity of Illness Index: Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.Tuberculosis, Spinal: Osteitis or caries of the vertebrae, usually occurring as a complication of tuberculosis of the lungs.Arthritis, Reactive: An aseptic, inflammatory arthritis developing secondary to a primary extra-articular infection, most typically of the GASTROINTESTINAL TRACT or UROGENITAL SYSTEM. The initiating trigger pathogens are usually SHIGELLA; SALMONELLA; YERSINIA; CAMPYLOBACTER; or CHLAMYDIA TRACHOMATIS. Reactive arthritis is strongly associated with HLA-B27 ANTIGEN.Arthritis, Psoriatic: A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.Rheumatic Diseases: Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.Balneology: Therapy by various hot or warm baths in natural mineral waters, spas, or "cures". It includes not only bathing in, but also drinking the waters, but it does not include whirlpool baths (HYDROTHERAPY).Uveitis, Anterior: Inflammation of the anterior uvea comprising the iris, angle structures, and the ciliary body. Manifestations of this disorder include ciliary injection, exudation into the anterior chamber, iris changes, and adhesions between the iris and lens (posterior synechiae). Intraocular pressure may be increased or reduced.Lumbar Vertebrae: VERTEBRAE in the region of the lower BACK below the THORACIC VERTEBRAE and above the SACRAL VERTEBRAE.Kyphosis: Deformities of the SPINE characterized by an exaggerated convexity of the vertebral column. The forward bending of the thoracic region usually is more than 40 degrees. This deformity sometimes is called round back or hunchback.Arthritis, Rheumatoid: A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.Thoracic Vertebrae: A group of twelve VERTEBRAE connected to the ribs that support the upper trunk region.HLA Antigens: Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.Cervical Vertebrae: The first seven VERTEBRAE of the SPINAL COLUMN, which correspond to the VERTEBRAE of the NECK.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Osteitis: Inflammation of the bone.Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)Anti-Inflammatory Agents, Non-Steroidal: Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.Back Pain: Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions.Pseudarthrosis: A pathologic entity characterized by deossification of a weight-bearing long bone, followed by bending and pathologic fracture, with inability to form normal BONY CALLUS leading to existence of the "false joint" that gives the condition its name. (Dorland, 27th ed)Receptors, Tumor Necrosis Factor: Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.Spinal DiseasesTreatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Sacroiliitis: Inflammation of the SACROILIAC JOINT. It is characterized by lower back pain, especially upon walking, fever, UVEITIS; PSORIASIS; and decreased range of motion. Many factors are associated with and cause sacroiliitis including infection; injury to spine, lower back, and pelvis; DEGENERATIVE ARTHRITIS; and pregnancy.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Klebsiella: A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria whose organisms arrange singly, in pairs, or short chains. This genus is commonly found in the intestinal tract and is an opportunistic pathogen that can give rise to bacteremia, pneumonia, urinary tract and several other types of human infection.Psoas Abscess: Abscess of the PSOAS MUSCLES resulting usually from disease of the lumbar vertebrae, with the pus descending into the muscle sheath. The infection is most commonly tuberculous or staphylococcal.

*  Ankylosing Spondylitis | Regional Medical Center

Learn more about Ankylosing Spondylitis at Regional Medical Center of San Jose DefinitionCausesRisk ... Ankylosing spondylitis. Spondylitis Association of America website. Available at: http://www.spondylitis.org/About-Spondylitis/ ... The cause of ankylosing spondylitis is not known. Some cases may be associated with a problem in a specific gene. ... Diagnosis is based on common symptoms of ankylosing spondylitis, such as:. *Dramatic loss of motion of the lower back and spine ...

*  Ankylosing Spondylitis News, Research

Ankylosing Spondylitis News and Research. RSS Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis ... suffer from Ankylosing Spondylitis. Further Reading. *What is Ankylosing Spondylitis? ... NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis Novartis announced today that the results of the ... Novartis' Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients Novartis announced today ...
https://news-medical.net/?tag=/Ankylosing Spondylitis

*  Improving mobility in ankylosing spondylitis patients

Most patients who are given the diagnosis of ankylosing spondylitis have no idea what the disease is all about. Essentially, ... Improving mobility in ankylosing spondylitis patients 2015-09-03. /0 Comments/in Announcements, BC Chiropractic Association, ... You are here: Home / NEWS / Announcements / Improving mobility in ankylosing spondylitis patients ... Essentially, ankylosing spondylitis is a form of inflammatory arthritis that localizes in the spine. Because it is an auto- ...

*  Study Evaluating Predictors of Response in Patients With Ankylosing Spondylitis - Full Text View - ClinicalTrials.gov

Spondylitis. Spondylitis, Ankylosing. Bone Diseases, Infectious. Infection. Bone Diseases. Musculoskeletal Diseases. Spinal ... Study Evaluating Predictors of Response in Patients With Ankylosing Spondylitis (PRETEA). This study has been completed. ... Percentage of Participants With Assessment in Ankylosing Spondylitis (ASAS) 40 Response at Week 16 [ Time Frame: Week 16 ]. ... Success and Failure of Biological Therapy: Predictors of Response in Patients With Active Ankylosing Spondylitis. ...
https://clinicaltrials.gov/ct2/show/NCT00900796?cond="ankylosing spondylitis"&rank=10

*  5 Best Exercises and Other Tips for Ankylosing Spondylitis

Learn about five safe and effective exercises for strengthening the neck and back with ankylosing spondylitis, plus other tips ... The Progression of Ankylosing Spondylitis Learn the effects and progression of ankylosing spondylitis and how the condition can ... Video: Symptoms of Ankylosing Spondylitis The signs and symptoms of ankylosing spondylitis are different than ordinary back ... Most Effective Ankylosing Spondylitis Exercises. Written by Ann Pietrangelo. Medically Reviewed on March 10, 2017 by Gregory ...

*  Spondylitis erosiva: report on 9 patients. | Annals of the Rheumatic Diseases

On the basis of these observations it is considered that 7 of these 9 patients had ankylosing spondylitis, the erosive lesions ...

*  Ankylosing Spondylitis | Active Studies | Pinnacle

Have you been diagnosed with Ankylosing Spondylitis We are currently seeking volunteers for a clinical research study of an ... Have you been diagnosed with Ankylosing Spondylitis? We are currently seeking volunteers for a clinical research study of an ...

*  Ankylosing Spondylitis Patients Commencing Biologic Therapy Have High Baseline Levels of Comorbidity: A Report from the...

Total ankylosis spine (defined by syndesmophytes present on the lateral views of spinal radiographs at all intervertebral levels from T6 through S1); any other inflammatory rheumatic disease; fibromyalgia; a serious infection within 2 months prior to randomization; TB; (active or latent) or recent contact with a person with active TB; an opportunistic infection within 6 months of screening; hepatitis; HIV; a transplanted organ; malignancy; multiple sclerosis; congestive heart failure; taking sulfasalazine or methotrexate within 2 weeks prior to screening; systemic corticosteroids within 1 month prior to screening; anti-TNF therapy other than infliximab within 3 months prior to screening; infliximab at any other time prior to screening; taking DMARDS other than sulfasalazine or methotrexate within 6 months prior to screening or cytotoxic drugs within 12 months of screening ...

*  Video: Symptoms of Ankylosing Spondylitis

The signs and symptoms of ankylosing spondylitis are different than ordinary back pain. Learn when your should consult a ... How Do I Know I Have Ankylosing Spondylitis?. How Do I Know I Have Ankylosing Spondylitis?. Learn the most common symptoms for ... Other Side Effects of Ankylosing Spondylitis. Other Side Effects of Ankylosing Spondylitis. Find out about some of the less ... Treatment for Ankylosing Spondylitis. Treatment for Ankylosing Spondylitis. Explore all treatment options, including medication ...

*  Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis - Full Text View - ClinicalTrials.gov

Spondylitis. Spondylitis, Ankylosing. Bone Diseases, Infectious. Infection. Bone Diseases. Musculoskeletal Diseases. Spinal ... Ankylosing Spondylitis Quality of Life (ASQoL) Total Score Change From Baseline [ Time Frame: Baseline and 16 Weeks ]. ASQoL is ... It consists of 18 statements that are relevant to the physical and mental conditions for a patient with Ankylosing Spondylitis ... Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20) [ Time Frame: 16 weeks ]. ASAS measures symptomatic ...
https://clinicaltrials.gov/ct2/show/NCT00247962?term=Ankylosing Spondylitis&rank=10

*  Ankylosing spondylitis | Define Ankylosing spondylitis at Dictionary.com

Ankylosing spondylitis definition, a degenerative inflammatory disease, most common in young men, characterized by back pain ... ankylosing spondylitis in Medicine Expand. ankylosing spondylitis n. Arthritis of the spine, resembling rheumatoid arthritis ... Also called Strümpell-Marie disease, Marie-Strümpell disease, rheumatoid spondylitis, Strümpell-Marie disease. ... British Dictionary definitions for ankylosing spondylitis Expand. ankylosing spondylitis. noun 1. (med) inflammation of the ...

*  Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to...

Mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for Participants With Ankylosing Spondylitis (AS) at Baseline ... ankylosing spondylitis psoriatic arthritis rheumatoid arthritis MedlinePlus related topics: Ankylosing Spondylitis Arthritis ... Spondylitis. Spondylitis, Ankylosing. Joint Diseases. Musculoskeletal Diseases. Rheumatic Diseases. Connective Tissue Diseases ... Mean Bath Ankylosing Spondylitis Functional Index (BASFI) Scores at Baseline, and Months 3, 6, 9, and 12 [ Time Frame: Baseline ...

*  Histopathology of the synovial membrane of peripheral joints in ankylosing spondylitis. | Annals of the Rheumatic Diseases

The histological features of the synovial membrane of peripheral joints in ankylosing spondylitis are similar to those seen in ... Peroxidase-antiperoxidase staining shows the presence of IgG-, IgA-, and IgM-containing plasma cells in ankylosing spondylitis ... The percentage of IgM-containing cells is significantly lower in ankylosing spondylitis than in rheumatoid arthritis. ...

*  DMOZ - Health: Conditions and Diseases: Musculoskeletal Disorders: Arthritis: Ankylosing Spondylitis

Ankylosing Spondylitis is a painful disease which causes increasing stiffness and rigidity of the spine. Untreated, this can ... Spondylitis Association of America Supports education, research and treatment for ankylosing spondylitis and related diseases. ... "Health ... Ankylosing Spondylitis" search on: AOL - Ask - Bing - DuckDuckGo - Gigablast - Google - ixquick - Yahoo - Yandex - ... National Ankylosing Spondylitis Society A resource for sufferers. Information about the disease, with practical advice on daily ...

*  Suffering from ankylosing spondylitis. Prescribed infliximab rimecade, pain returns after temporary relief. Permanent cure? -...

Permanent cure?. Ask a Doctor about diagnosis, treatment and medication for Ankylosing spondylitis, Ask a Neurologist ... Suffering from ankylosing spondylitis. Prescribed infliximab rimecade, pain returns after temporary relief. ... Suffering from ankylosing spondylitis. Prescribed infliximab rimecade, pain returns after temporary relief. Permanent cure?. ... M25 years male 85kg I have Ankylosing spondylitis I received treatment ( infliximab rimecade 100mg) as the following dose (0-2- ...

*  Ankylosing spondylitis - NHS Choices

Read about ankylosing spondylitis (AS), a long-term (chronic) condition in which the spine and other areas of the body become ... Read about the causes of ankylosing spondylitis.. Treating ankylosing spondylitis. There's no cure for AS and it's not possible ... Read about diagnosing ankylosing spondylitis.. Causes of ankylosing spondylitis. It's not known what causes the condition, but ... Read about treating ankylosing spondylitis.. Complications of ankylosing spondylitis. The outlook for AS is highly variable. ...

*  Ankylosing Spondylitis/Rheumatoid Arthritis Fund | Eric Brunning-Snow's Fundraiser

Ankylosing Spondylitis attacks my Spine and makes it Bamboo like. And by the time im 35-40 years old I will need Metal rods put ... I am 23 and i live with Ankylosing Spondylitis & Rheumatoid Arthritis. I Need help raising money for living exp & a $500 ... Ankylosing Spondylitis attacks my Spine and makes it Bamboo like. And by the time im 35-40 years old I will need Metal rods put ... I am 23 and i live with Ankylosing Spondylitis & Rheumatoid Arthritis. I Need help raising money for living exp & a $500 ...

*  Ankylosing Spondylitis - Arthritis Message Board - HealthBoards

Ankylosing Spondylitis julie2424. Arthritis. 18. 07-08-2009 06:07 AM. ankylosing spondylitis and Growth Hormone lwgy. Arthritis ... Re: Ankylosing Spondylitis Hi. I also have Ankylosing Spondylitis, I have been on celebrex for a year and not helping as it ... Ankylosing Spondilitis karloff. Arthritis. 22. 01-31-2005 07:29 AM. We Know What He Has - Ankylosing Spondylitis AMIEAMAM. ... Re: Ankylosing Spondylitis Hey As sufferers, i hope all is well. I have my first Rheumy appt. next week and like i said the dr ...

*  Expected duration of Ankylosing Spondylitis | Ankylosing Spondylitis

Ankylosing spondylitis (AS) is a chronic arthritis, which cannot be cured. Symptoms and progression of the disease can be ... Ankylosing Spondylitis: When should one seek medical help?Treatment Options for Ankylosing Spondylitis ... Ankylosing spondylitis (AS) is a chronic inflammatory arthritis, which affects the joints of the spine and the joints between ... With progression of the disease, inflammation of the spine (spondylitis) can lead to a complete cementing together (fusion) of ...

*  Anklyosing spondilitis - Answers on HealthTap

A severe case of ankylosing spondylitis can make it impossible for you to lift your head high enough to see forward. for topic ... Bensinger on anklyosing spondilitis: Ankylosing spondylitis is an inflammatory disease that can cause some of the vertebrae in ... Spondylitis (Definition) An inflammatory condition of the spine such as ankylosing spondylitis. Spondy = spine & -itis = ... Let us try to help: Ankylosing spondylitis is an inflammatory disease that can cause some of the vertebrae in your spine to ...

*  Is there an Ankylosing Spondylitis med that I can take while on Cymbalta?

... ankylosing spondylitis - Additional details: I am about to get my diagnosis of AS. I am looking at the meds given for ... ... Home › Q & A › Questions › Is there an Ankylosing.... Is there an Ankylosing Spondylitis med that I can take while on Cymbalta? ... cymbalta, ankylosing spondylitis, rheumatoid arthritis, spondyloarthritis, diagnosis. Details:. I am about to get my diagnosis ... Ankylosing Spondylitis - I was diagnosed with AS last year. I was on Cymbalta for about 2 years and?. Posted 19 Feb 2016 • 1 ...

*  Ankylosing Spondylitis | Doctors Hospital

Learn more about Ankylosing Spondylitis at Doctors Hospital of Augusta DefinitionCausesRisk ... Ankylosing spondylitis. Spondylitis Association of America website. Available at: http://www.spondylitis.org/About-Spondylitis/ ... The cause of ankylosing spondylitis is not known. Some cases may be associated with a problem in a specific gene. ... Diagnosis is based on common symptoms of ankylosing spondylitis, such as:. *Dramatic loss of motion of the lower back and spine ...

*  Ankylosing spondylitis - Causes - NHS Choices

In ankylosing spondylitis (AS) several parts of the lower spine become inflamed, including the bones in the spine (vertebrae) ... Read about how ankylosing spondylitis is diagnosed.. Can ankylosing spondylitis be inherited?. AS can run in families, and the ... In ankylosing spondylitis (AS) several parts of the lower spine become inflamed, including the bones in the spine (vertebrae) ... reliable method of diagnosing the condition because some people can have the HLA-B27 gene but not have ankylosing spondylitis. ...

*  Vent: No, I'm not pregnant, just bloated!! - Crohn's Disease - HealingWell.com Forum

Ankylosing Spondylitis. Uveitis. Back on Prednisone - I hate it. Methotrexate. Ranitidine HCL Prednisone 1% (eye drops). ...

*  Herbal Remedies for Rheumatic Heart Disease - Symptoms, Diagnosis, Effects, Herbs

Ankylosing Spondylitis. *Anti-Ageing. *Anal Fistula. *Anemia. *Atopic Dermatitis. *Autoimmune Disorders. *Bacterial Vaginosis ...

SpondylitisHLA-B38: HLA-B38 (B38) is an HLA-B serotype. The serotype identifies the B*38 allele products of the HLA-B gene-locus.Sacroiliac joint dysfunction: Sacroiliac joint dysfunction, also called sacroiliac joint disorder, sacroiliac joint disease, sacroiliac joint syndrome or sacroiliac syndrome, or "sacroilliac dysfunction and instability", generally refers to pain in the sacroiliac joint region that is caused by abnormal motion in the sacroiliac joint, either too much motion or too little motion. It typically results in inflammation of the sacroiliac joint, and can be debilitating.AnakinraAutomated analyser: An automated analyser is a medical laboratory instrument designed to measure different chemicals and other characteristics in a number of biological samples quickly, with minimal human assistance.Arthritis Research UKRed eye (medicine)Reactive arthritisDactylitis: Dactylitis or sausage digit is inflammation of an entire digit (a finger or toe), and can be painful.Annals of the Rheumatic Diseases: The Annals of the Rheumatic Diseases is a peer-reviewed medical journal. It is co-owned by the BMJ Group and the European League Against Rheumatism and covers all aspects of rheumatology, including musculoskeletal conditions, arthritis, and connective tissue diseases.Balneotherapy: Balneotherapy ( "bath") is the treatment of disease by bathing, usually practiced at spas. While it is considered distinct from hydrotherapy, there are some overlaps in practice and in underlying principles.UveitisACR score for rheumatoid arthritis: ACR score is a scale to measure change in rheumatoid arthritis symptoms. It is named after the American College of Rheumatology.Clay-shoveler fracture: Clay-shoveler's fracture is a stable fracture through the spinous process of a vertebra occurring at any of the lower cervical or upper thoracic vertebrae, classically at C6 or C7. In Australia in the 1930s, men digging deep ditches tossed clay 10 to 15 feet above their heads using long handled shovels.HLA B7-DR15-DQ6Cervical fractureCD4 immunoadhesin: CD4 immunoadhesin is a recombinant fusion protein consisting of a combination of CD4 and the fragment crystallizable region.Osteitis pubisSulfasalazineCelecoxibPseudarthrosisTACI-CRD2 protein domain: In molecular biology, this protein domain, TACI-CRD2 represents the second cysteine-rich protein domain found in the TACI family of proteins. Members of this family are predominantly found in tumour necrosis factor receptor superfamily, member 13b (TACI), and are required for binding to the ligands APRIL and BAFF.Cervical spine disorder: Cervical Spine Disorders are illnesses that are relatively detrimental to ones physical health. These ailments exist in the cervical spine which is made up of the upper first seven vertebrae, encasing and shielding the Spinal cord.Monoclonal antibody therapyKlebsiella terrigena: Klebsiella terrigena is a Gram-negative bacterial species of the genus Klebsiella. It has primarily been isolated from soil and water samples, but rarely from humans.Psoas muscle abscess

(1/1240) Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27).

Histocompatibility (HLA) antigen phenotypes have been studied in 100 patients with ulcerative colitis, 100 with Crohn's disease, and 283 normal controls. In addition the incidence of ankylosing spondylitis, sacroiliitis, and "enteropathic" peripheral arthropathy was determined in the patients with inflammatory bowel disease (IBD). There was no significant difference in antigen frequency between patients and controls. However, the incidence of HLA-B27 was increased in the patients complicated by ankylosing spondylitis and/or sacroiliitis in both ulcerative colitis and Crohn's disease. In contrast, none of the 29 IBD patients with "enteropathic" peripheral arthropathy had B27 antigen. Furthermore, ankylosing spondylitis was found more frequently in ulcerative colitis bearing HLA-B27 compared with non-B27 patients (P less than 0-01). The same was found in Crohn's disease, although this difference was not statistically significant. In addition, 12 of 14 ulcerative colitis patients and five out of six Crohn's patients with HLA-B27 had total colitis, compared with the frequency of total colitis in non-B27 patients (P less than 0-024 and less than 0-03 respectively). The data suggest that B27 histocompatibility antigen could be a pathogenetic discriminator between the arthropathies in IBD and may be of prognostic significance with respect to extension and severity of the disease.  (+info)

(2/1240) Cauda equina syndrome in ankylosing spondylitis: a report of six cases.

Six patients with ankylosing spondylitis and features of a cauda equina syndrome are described. The myelographic findings are discussed in relation to the pathogenesis of the disorder and its natural history. Present experience suggests that the cauda equina syndrome is a more common complication of ankylosing spondylitis than is usually thought.  (+info)

(3/1240) Cervical spondylotic myelopathy in elderly people: a high incidence of conduction block at C3-4 or C4-5.

OBJECTIVES: To precisely localise the site of conduction block in elderly patients with cervical spondylotic myelopathy in the presence of multilevel compression shown by MRI. METHODS: A total of 44 patients aged 65 and older underwent serial intervertebral recording of spinal somatosensory evoked potentials (SSEPs) from either the intervertebral disc or the ligamentum flavum after epidural stimulation. The site of conduction block identified by abrupt reduction in size of the negative peak was designated as the 0 level with the other levels numbered in order of distance assigning a minus sign caudally. RESULTS: A single site of focal conduction block was disclosed in 42 patients, 23 (55%) at C3-4, 17 (40%) at C4-5, and two (5%) at C5-6. At these levels (0), the amplitude of the negative component was reduced (p<0.0001) to 29% and the area to 22%, with a concomitant increase (p<0.0001) of the initial positive component to 150% in amplitude and 293% in area as compared to the-2 level which was taken as the baseline (100%). CONCLUSIONS: A high incidence (95%) of focal conduction block at C3-4 or C4-5 with normal conduction at C5-6 and C6-7 characterises cervical spondylotic myelopathy in elderly people. Incremental SSEP studies documenting the site of conduction block will help exclude clinically silent cord compression, directing the surgical intervention to the appropriate level of concern.  (+info)

(4/1240) Immune function in ankylosing spondylitics and their relatives: influence of disease and HLA B27.

So as to distinguish the separate influences of ankylosing spondylitis (AS) and possible HLA B27 associated immune response genes on immune response patterns, a battery of immunological tests were performed on fourteen patients with AS and their first-degree relatives. Previously unrecognized AS was detected by clinical and radiological means. Individuals with ankylosing spondylitis had significantly higher serum IgG and IgA concentrations than both their B27 positive and B27 negative relatives. B27 positive relatives had significantly lower phytohaemagglutinin (PHA) lymphocyte transformations than B27 negative relatives (P less than 0.01), while there was no difference between the ankylosing spondylitic and B27 positive groups. Antibody titres to Streptokinase/Streptodornase were significantly higher in the B27 positive individuals, with or without AS, than their B27 negative relatives (P less than 0.005 and P less than 0.02 respectively). These results show that serum immunoglobulin differences were associated with disease, while differences in PHA stimulation and varidase antibody titres were associated with the B27 antigen. These findings may indicate the presence of HLA associated immune response genes including those involved with reactions to a particular antigenic component of Streptokinase/Streptodornase.  (+info)

(5/1240) Predominance of mononuclear cells expressing the chemokine receptor CCR5 in synovial effusions of patients with different forms of arthritis.

OBJECTIVE: To study the role of the chemokine receptors CCR5 and CCR2 in patients with arthritis. METHODS: CCR5 expression on peripheral blood leukocytes was compared with the expression on leukocytes isolated from the synovial fluid of 20 patients with different rheumatic joint diseases. Three additional samples were studied for CCR2 expression. The expression of chemokine receptors on blood and synovial fluid leukocytes was determined by 3-color flow cytometry analysis. To test CCR5 receptor down-modulation from the cell surface, leukocytes were incubated in vitro with a RANTES (regulated on activation, normal T cell expressed and secreted) derivative, aminooxypentane (AOP)-RANTES. Patients were genotyped for the delta32 CCR5 deletion by polymerase chain reaction. RESULTS: A high percentage of CCR5-expressing CD4+ and CD8+ T cells (74% and 81%, respectively), monocytes (51%), and natural killer cells (35%) was found in the synovial fluid of all patients, whereas in the peripheral blood, only a small percentage of these cells expressed CCR5 (13%, 32%, 7.8%, and 4%, respectively). Infiltration of CCR5-positive leukocytes was not reduced in CCR5-heterozygous patients. A similar, but less pronounced, distribution was observed for CCR2-positive T cells. In vitro, CCR5 was completely down-modulated on synovial fluid leukocytes by AOP-RANTES. CONCLUSION: The predominance of CCR5-positive mononuclear cells in the synovial effusions of patients with arthritis suggests an important role for CCR5 in the process of joint inflammation, and identifies CCR5 as a possible new target for therapeutic intervention.  (+info)

(6/1240) Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial.

OBJECTIVE: To consider the relevance of the duration of a clinical trial in ankylosing spondylitis: long-term (i.e. 1 yr) vs short-term (i.e. 6 weeks) assessment of a non-steroidal anti-inflammatory drug (NSAID)-placebo controlled study. METHODS: The design was a prospective, multicentre, double-blind, placebo-controlled study of 6 weeks duration with a 12 months double-blind extension. Study drugs were placebo (n = 121) or active NSAID (n = 352). A decrease of at least 50% in pain and/or global assessment and/or functional impairment during the study defined the response to treatment. The percentage of patients discontinuing the study drug over time (life table analysis) permitted the evaluation of both the efficacy and toxicity. RESULTS: Among the 473 recruited patients, the percentage of responders was similar at 1 yr and week 6 with a highly statistically significant difference in favour of the active NSAID groups when compared to placebo (at 1 yr, 17% in the placebo group vs 37, 50 and 43% in the piroxicam 20 mg, meloxicam 15 mg and meloxicam 22.5 mg, respectively, for the patient's overall assessment) without any statistically significant difference between the three active groups. However, evaluation of the patients discontinuing the study drug during the 1 yr of the study permitted the detection of a statistically significant difference between the active NSAID groups. A lower percentage of patients taking meloxicam 22.5 mg had to discontinue the study drug when compared to either meloxicam 15 mg or piroxicam 20 mg (37% vs 53% and 53%, respectively, P < 0.05). By 52 weeks, drug-related upper gastrointestinal adverse events occurred in 13, 32, 20 and 18% in the placebo, piroxicam 20 mg, meloxicam 15 mg and meloxicam 22.5 mg groups, respectively. Some of the adverse events occurred only after week 6. CONCLUSION: This study suggests that a 1 yr trial might be of optimum value compared to a 6 week assessment in order to define better the efficacy and tolerability of NSAIDs in ankylosing spondylitis.  (+info)

(7/1240) Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis.

OBJECTIVE: In this study, we aimed to determine the urinary levels of pyridinium cross-links and urinary beta-isomerized fragments derived from the C-telopeptide of the alpha1 chain of type I collagen (beta-CTX) as markers of bone resorption in patients with ankylosing spondylitis (AS), and to study their relationship to markers of disease activity [erythrocyte sedimentation rate (ESR)] and to disease subsets of this condition. METHODS: The serum calcium, osteocalcin (OC), parathormone (PTH), 25 OHD3 levels, beta-CTX and the urinary combined free pyridinolines (f-Pyr + f-Dpyr), urinary free deoxypyridinoline (f-Dpyr) and urinary free pyridinoline (f-Pyr) were evaluated and compared in 32 AS patients and 25 controls. Bone mineral density (BMD) was evaluated at the lumbar spine and the femoral neck. RESULTS: The serum markers of bone metabolism (serum calcium, PTH, 25 OHD3 and OC) were in the normal range in the AS group. AS patients had a lowered lumbar spine BMD (P = 0.01) (corresponding T score: P = 0.03), but femoral neck BMD did not differ significantly between AS and controls (P = 0.08) (corresponding T score: P = 0.11). There was no difference in the urinary levels of pyridinium cross-links and beta-CTX between AS patients and controls. A positive correlation between ESR, (f-Pyr + f-Dpyr) (r = 0.42; P = 0.018) and f-Dpyr (r = 0.49; P = 0.005) was observed. In the different disease subsets of AS, we found that patients with peripheral involvement had higher (f-Pyr + f-Dpyr) (P = 0.04) and f-Dpyr levels (P = 0.04), patients with early disease had elevated (f-Pyr + f-Dpyr) (P = 0.01), f-Dpyr (P = 0.02) and f-Pyr (P = 0.01) levels, and that those with raised ESR had enhanced f-Dpyr (P = 0.009) excretion. Patients were then stratified according to disease duration, peripheral involvement and sex, and this allowed us to observe that only urinary f-Dpyr remained elevated in patients independently from these variables and that raised ESR is the more relevant parameter for explaining this high level of excretion. CONCLUSION: We conclude that there was no difference in the levels of urinary pyridinium cross-links and beta-CTX between AS and controls. However, urinary excretion of some of these collagen compounds was enhanced in subgroups of AS, mainly in patients with raised ESR. Thus, AS patients with laboratory evidence of active disease could have a higher risk of bone loss.  (+info)

(8/1240) Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis.

OBJECTIVE: To examine the expression of the matrix metalloproteinase, MMP-1, and the cysteine proteases, cathepsin B (CB) and cathepsin L (CL), in the synovial membrane (SM) of patients with early inflammatory arthritis. METHODS: Samples of SM were obtained by blind needle biopsy or needle arthroscopy from inflamed knees of 28 patients with early inflammatory arthritis (mean disease duration 10.2 months, range 2 weeks-18 months). Sixteen patients had rheumatoid arthritis (RA), nine psoriatic arthritis and there was one each with ankylosing spondylitis, gout and an undifferentiated arthritis. Comparison was made with tissue from two patients with established erosive RA and three normal synovial tissue samples. In situ hybridization was performed using digoxigenin-labelled RNA probes. RESULTS: MMP-1, CB and CL were expressed in all patients with early arthritis and in established erosive RA, whereas normal synovium showed only scanty expression. The three proteases were prominent in perivascular infiltrates and endothelial cells of early arthritis tissue. MMP-1 was observed primarily in the lining layer, but was also evident in the sublining area. CB and CL were expressed to a lesser extent in the lining layer, and were present mainly in the subintima. The three proteases were not found in lymphoid aggregrates. No differences were observed between the disease categories. CONCLUSIONS: The detection of MMP-1, CB and CL in the synovium shortly after symptom onset implies that the potential for joint destruction exists at a very early stage in the disease. In addition, the perivascular and endothelial cell expression suggests a role for these proteases in mononuclear cell influx to the inflamed synovium and in angiogenesis.  (+info)

psoriatic arthritis

  • When grouped together, they are termed as "Spondyloarthropathy" and include conditions like ankylosing spondylitis , psoriatic arthritis , etc. (epainassist.com)


  • There are other types of arthritis that affect the SI joints, namely gout, rheumatoid arthritis and ankylosing spondylitis, a type of inflammatory arthritis that always affects the SI joints. (brentbowenmd.com)
  • Additional causes of iritis include blunt force trauma and certain diseases, including ankylosing spondylitis, sarcoidosis, Reiter syndrome, inflammatory bowel disease and psoriasis. (reference.com)